Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
Germline genetic aberrations relevant to myeloid cell biology can predict toxicity and efficacy of CART in patients with LBCL. Elucidating such intrinsic determinants may help improve patient selection and develop strategies to enhance the therapeutic index of CART.
Authors
- Jason R. Westin (ORCID: https://orcid.org/0000-0002-1824-2337)
- Jeremy Ramdial (ORCID: https://orcid.org/0000-0002-8984-3420)
- Sherry Adkins (ORCID: https://orcid.org/0000-0001-6290-904X)
- Neeraj Y. Saini (ORCID: https://orcid.org/0000-0001-7435-0933)
- Paolo Strati (ORCID: https://orcid.org/0000-0002-7445-1459)
- Jared Henderson (ORCID: https://orcid.org/0000-0002-5121-5234)
- Sairah Ahmed (ORCID: https://orcid.org/0000-0001-7302-8299)
- Amanda Brandt (ORCID: https://orcid.org/0000-0002-1617-0771)
- Sattva Swarup Neelapu (ORCID: https://orcid.org/0000-0003-1045-4914)
- Partow Kebriaei (ORCID: https://orcid.org/0000-0002-8607-9404)
- Anath C. Lionel (ORCID: https://orcid.org/0000-0001-7174-7070)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Michelle A T Hildebrandt
- Elizabeth J. Shpall
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012401
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- Moonshot Research and Development Program